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The inﬂuence of thyroid diseases, diabetes
mellitus, primary hyperparathyroidism, vitamin
B12 deﬁciency and other comorbid autoimmune
diseases on treatment outcome in patients
with rheumatoid arthritis
An exploratory cohort study
Amir Emamifar, MDa,b,
∗
, Inger Marie Jensen Hansen, PhD, DMScib,c,d
Abstract
To investigate the impact of comorbid diseases on rheumatoid arthritis (RA) outcome.
All patients diagnosed with RA since 2006, who were registered in our local Danbio registry, were included in this cohort study.
Patients’ demographics, serology results, and Disease Activity Score in 28 joints-C-reactive protein (DAS28-CRP) at the time of
diagnosis and after 4 months of treatment initiation were collected. Patients’ electronic hospital records were evaluated for a positive
history of thyroid diseases, diabetes mellitus, primary hyperparathyroidism, vitamin B12 deﬁciency, and the presence of other
diagnosed autoimmune diseases.
1035 RA patients were included. The observed prevalence of thyroid diseases was 11.8%, DM 10.4%, primary
hyperparathyroidism 2.8%, vitamin B12 deﬁciency 5.8%, and other diagnosed autoimmune diseases 1.6%. There were signiﬁcant
associations between presence of thyroid diseases and female gender (P< .001); DM and greater age (P< .001); primary
hyperparathyroidism and longer disease duration (P= .002); other diagnosed autoimmune diseases and antinuclear antibody
positivity (P< .001). RA patients with thyroid diseases (P= .001) and other comorbid autoimmune diseases (P< .001) had
signiﬁcantly poorer initial response to the RA treatment compared to patients with isolated RA.
Univariate analyses revealed that age, the presence of thyroid diseases, the presence of other diagnosed autoimmune diseases
and DAS28-CRP at the time of diagnosis were signiﬁcantly associated with DDAS28-CRP. Additionally, multivariate analysis
demonstrated that DDAS28-CRP deterioration was signiﬁcantly correlated to the presence of thyroid diseases (unstandardized
regression coefﬁcient (standard error);0.188(0.088), P= .030) and the presence of other diagnosed autoimmune diseases (-0.537
(0.208),P= .010).
RA patients are at increased risk of speciﬁc comorbidities with possible impact on the treatment outcome. To improve this
situation, periodic assessment of comorbidities should be considered.
Abbreviations: ACR= American College of Rheumatology, ANA= antinuclear antibody, anti-ccp= anticyclic citrullinated peptide
antibody, DAS28-CRP = disease activity score in 28 joints-C-reactive protein, DM = diabetes mellitus, EULAR = the European
League Against Rheumatism, FBS = fasting blood sugar, HbA1C = hemoglobin A1C, HLA = human leukocyte antigen, IgM-RF =
immunoglobulin M rheumatoid factor, MMA = methylmalonic acid, PTH = parathyroid hormone, RA = rheumatoid arthritis, SJ =
swollen joints, T3 = triiodothyronine, T4 = thyroxine, TJ = tender joints, TNF-a = tumor necrosis factor alpha, TSH = thyroid
stimulating hormone.
Keywords: autoimmune diseases, comorbidity, disease activity score in 28 joints-C-reactive protein, rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease,
with a prevalence of 0.5% to 1% in the general population that
predominantly affects joints. However, patients with RA may
present with extra articular presentations.[1–2] Additionally, there
are various comorbidities that can complicate the course of RA
disease. The most common comorbidities among patients with
RA are cardiovascular events, infections, pulmonary diseases,
different types of cancers, depression, etc.[3] Besides, some of
these comorbidities are less frequently discussed in the literature,
for example, hearing loss.[4] RA comorbidities are associated
with loss of function, higher rate of hospitalization, increased
mortality rate as well as socioeconomic burden on the patients
and society.[3,5–6]
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The association between comorbid diseases and RA is a
complex dilemma. Comorbid diseases may present prior, later or
at the same time. They might be a consequence of RA treatment,
for example, corticosteroids or a predisposing factor can lead
both to RA and comorbid diseases, for example, smoking.[3,5]
Furthermore, RA comorbidities may present due to a shared
autoimmune pathology, described as polyautoimmunity or
multiple autoimmune syndrome .[7] RA comorbidities are often
underdiagnosed and undertreated.[8,9]
Given the importance of comorbid diseases in RA, it is
important to diagnose and subsequently treat such conditions in
RA patients, which is recommended by the European League
Against Rheumatism (EULAR).[10] In addition, thorough
investigation of comorbid diseases in RA can also aim to
understand the common pathological association.
Disease Activity Score in 28 joints-C-reactive protein (DAS28-
CRP) is a scoring system that is commonly used to evaluate
treatment response as well as monitoring disease activity in
clinical practice. It is derived from 2 subjective parameters, that is,
tender joints (TJ) count and patient global assessment and 2
objective parameters, that is, swollen joints (SJ) count and
laboratory value of CRP.[11] DAS28-CRP is a valuable tool to
optimize outcome in RA patients, by means of measuring disease
activity and thereafter adjusting treatment, that is, “treat-to-
target.”[11]
The primary objective of this studywas to reveal the prevalence
of important comorbidities i.e thyroid disease, diabetes mellitus
(DM), primary hyperparathyroidism, and vitamin B12 deﬁciency
as well as other comorbid autoimmune diseases in our RA
patients. Furthermore, we investigated the possible associations
between clinical characteristic of RA and these comorbidities. At
last, the effect of these comorbidities on initial treatment response
was evaluated with the aim of DAS28-CRP, since the initial
treatment response is an independent prognostic factor.[12–14]
The relationship between RA and thyroid diseases has been
discussed in previous studies, in which indicates higher
prevalence of thyroid diseases in RA patients compared to the
general population (about 2–3 times).[15–17] The most accepted
pathology is autoimmunity where human leukocyte antigen
(HLA) gene complex plays a signiﬁcant role.[18]
There are inconsistencies regarding the prevalence of DM in
RA, however the previous research support the increased
prevalence of DM or insulin resistance in RA in many instances,
caused by immune system activation and/or RA treatment.[19,20]
Tumor necrosis factor alpha (TNF-a) is a mediator of insulin
resistance and has a major role in the pathogenesis of RA.[21,22]
Additionally, TNF-a inhibitors reduces the risk of developing
DM in RA patients, in which emphasizes the involvement of
TNF-a in the common pathogenesis between RA and DM.[23]
A connection between vitamin b12 deﬁciency and RA has been
suggested before, probably due to deﬁcient nutrition and eventual
malabsorption secondary to autoimmune mechanisms.[24–26]
Vitamin B12 may result in hyperhomocysteinemia which is an
independent risk factor for cardiovascular disease.[27,28] The
prevalence of vitamin B12 deﬁciency in patients with RA is
variable. This was reported equal to 4% by Pettersson et al,
24.9% by Segal et al, and 30% by Vreugdenhil et al.[24,29,30]
Primary hyperparathyroidism is a metabolic disorder of one or
more of the parathyroid glands with a prevalence of 1 to 7 per
1000 adults.[31] The presence of primary hyperparathyroidism in
RA patients may aggravate the effect of RA on bones and joints
by means of interaction with cytokines and inﬂammatory
markers involved in RA.[32]
2. Materials and methods
2.1. Danish danbio registry
The Danish Danbio registry was ﬁrstly established in 2000. It
provides nationwide data on the disease course of patients with
inﬂammatory rheumatic disease including RA via unique
personal identiﬁcation code. Danbio has been approved by
The Danish Data Registry (j. nr. 2007-58-0014 and j. nr. 2007-
58-0006), and National Board of Health (j. nr. 7-201-03-12/1)
and thereafter, since 2006, it became mandatory to report to the
registry why all newly diagnosed patients as well as patients
referred from other departments have been registered in Danbio.
Data are collected from patients and health personnel (nurses and
physicians) and are basically divided to baseline variables (e.g.,
demographic data, diagnosis, diseases duration) and Longitudi-
nal/follow up data (e.g., treatment, functional status, and disease
activity scores).[33] Each section of rheumatology has access to its
own patients. At our section of rheumatology, all patients with
diagnosis of RA are registered in Danbio at every consultation.
2.2. Study design and settings
This is an observational cohort study. The whole parts of the
study were performed at the section of rheumatology, Svendborg
Hospital in December 2016. The study was approved by Danish
Data Protection Agency (ﬁle no. 14/50243) and Danish Patient
Safety Authority (ﬁle no. 3-3013-1542/1/).
2.3. Participants
All patients with diagnosis of RA registered inDanbio since 2006,
were considered to enter into the study. The diagnosis of RA was
established according to the 1987 American College of
Rheumatology (ACR) criteria for RA (old criteria) and, since
2010, based on the 2010 ACR/EULAR criteria for RA (new
criteria).[34,35] Inclusion criteria were as follows: Patients who
were registered at the rheumatology section of Svendborg
hospital, age ≥ 18 years old. Patients who passed away or were
referred to the other departments were also included in the study.
Patients with juvenile RA were excluded from the study.
2.4. Initial rheumatoid arthritis treatment
At our section of rheumatology, patients with newly established
diagnosis of RA are initially treated with methotrexate, which
may be increased to 25mg per week, depends on DAS28-CRP as
an index of disease activity. Furthermore, treatment can be
supplemented by hydroxychloroquine and sulfasalazine as well
as prednisolone (given Intramuscular, intra-articular or orally) in
case of persistent inﬂammation. The treatment goal is to achieve
remission, that is, DAS28-CRP <2.6 (or low disease activity, i.e.,
DAS28-CRP3.2) as quickly as possible.
2.5. Data collection
Patients’ demographic data (age, sex, year of diagnosis), disease
duration, serology test results including immunoglobulin M
rheumatoid factor (IgM-RF), anticyclic citrullinated peptide
antibody (anti-ccp), and antinuclear antibody (ANA) were
extracted. DAS28-CRP at the time of diagnosis and after 4
months (±1–2 months) of treatment initiation was also collected.
The electronic hospital records of the patients for the last 10 years
(since 2006) were evaluated, to the extent data were available, for
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a positive history of thyroid diseases, DM, primary hyperpara-
thyroidism, vitamin B12 deﬁciency as well as the presence of
other diagnosed autoimmune diseases which is described with
details below:
2.5.1. Thyroid diseases.To detect thyroid diseases in this study,
we searched our patients’ electronic hospital records for any
positive history of thyroid diseases. Furthermore, results of
thyroid laboratory tests (triiodothyronine [T3], thyroxine [T4],
thyroid stimulating hormone [TSH]), as well as patients’
medication list were reviewed to ﬁnd any abnormal lab results
or use of thyroid medications to ﬁnd comorbid thyroid diseases.
Diagnosis of thyroid diseases were made at the section of
endocrinology based on routine follow up and updated guide-
lines. Patients with subclinical thyroid disease (increased or
decreased TSH, normal T3/T4, no clinical symptoms) were not
considered to estimate the prevalence of thyroid diseases, nor
used to perform other statistical analysis. The individual medical
records from family physicians were not examined in this study,
since we did not have access to such records.
2.5.2. Diabetes mellitus. Considering the possible relationship
between RA and DM, the electronic hospital records of the
patients were reviewed, in a similar way, for a positive history of
DM as well as prescribed antidiabetic medications and abnormal
lab tests (increased fasting blood sugar [FBS] and hemoglobin
A1C [HbA1C]) to identify whether the patients had been
diagnosed with DM as well. Types of DM were extracted from
Fyns Diabetes Database.
2.5.3. Primary hyperparathyroidism. Patients’ electronic hos-
pital records including laboratory results (parathyroid hormone
[PTH] and calcium levels) were reviewed to reveal if they had
been diagnosed with primary hyperparathyroidism. According to
the Danish endocrinology society, primary hyperparathyroidism
can be diagnosed as follows:
A plasma calcium concentration above the upper reference
range, where a plasma PTH concentration is measured in the
upper third or above the upper limit of the reference range.
With the 2nd generation of PTH assays, which is most
commonly used, a plasma PTH concentration >5 pmol /L will
be considered to be a disproportionately high PTH concentra-
tion in a patient with hypercalcemia. Hyperparathyroid
hypercalcemia state should be observed with at least 2
measurements and, besides, other causes of hyperparathyroid
hypercalcemia should be excluded (e.g., familial hypocalciuric
hypercalcemia, thiazide diuretics or lithium therapy as well as
tertiary hyperparathyroidism).[36]
2.5.4. Vitamin B12 deﬁciency. Diagnosis of vitamin B12
deﬁciency was established with respect to the serum level of
vitamin B12 and methylmalonic acid (MMA). The vitamin B12
deﬁciency was considered as vitamin B12<148pmol/L (<200
pgr/mL) as also suggested by previous studies. In case of vitamin
B12 between 148 to 258pmol/L (201–350pg/mL) MMA was
used to conﬁrm diagnosis. In addition to the laboratory results,
patients’ electronic hospital records and medication list were
also reviewed to ﬁnd patients with comorbid vitamin B12
deﬁciency.
2.5.5. Other diagnosed autoimmune comorbidities. During
data extraction, any other diagnosed autoimmune diseases were
found in patients’ electronic hospital records were collected.
Thereafter, patients autoantibodies proﬁle were also assessed to
explore any comorbid autoimmune diseases. Patients with only
positive autoantibodies proﬁle and without deﬁnite diagnosis
were not considered to perform statistical analysis.
2.6. Variables
Demographic data were extracted from Danbio. The results of
IgM-RF (normal range:<15IU/mL), anti-ccp (normal range:<
20EU/mL), and ANA (normal range:<1/0 IU) were collected
and analyzed both quantitative and qualitative (positive/nega-
tive). DAS28-CRP and DDAS28-CRP were calculated as follows:
DAS28-CRP=0.56
∗p
(Tender Joint) + 0.28
∗p
(Swollen Joint)
+ 0.36
∗
ln(CRP+1) + 0.014
∗
Global Visual Analog Scale + 0.96.
DDAS28-CRP=DAS281-CRP (at the time of diagnosis) –
DAS284-CRP (after 4 months of treatment initiation±1–2
months) representing initial treatment response. The lower
reporting limit of CRP was considered as<10 mg/L.[37]
The local laboratory reference values were as follows: TSH
(0.3–4mIU/L), T3 (1.3–2.2nmol/L), T4 (60–130nmol/L), FBS
(<126mg/dL), HbA1C (<6.5%), PTH (1.1–6.9pmol/L), calcium
(1.19–1.29mmol/L), vitamin B12 (130–700pmol/L), and MMA
(0.08–0.28mmol/L).
2.7. Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics
version 24.0. Continuous data were presented as mean±
standard deviation (±SD), categorical data as frequencies and
respective percentages. Comparisons of baseline demographics
and RA related characteristics, between groups with and without
speciﬁc comorbidity were made with Student’s t-test. When
comparing 2 binary variables the Chi-square was performed. The
P value was considered as signiﬁcant if P< .05. In case of missing
data, we used pairwise deletion to keeps as many cases as possible
for each analysis.
Univariate and multivariate analysis were performed to
delineate the relationship between the dependent variable, that
is, DDAS28-CRP and independent variables including: gender,
age, IgM-RF, anti-ccp, ANA, disease duration, presence of
thyroid diseases, presence of primary hyperparathyroidism,
presence of DM, presence of vitamin B12 deﬁciency, presence
of other diagnosed autoimmune diseases, TSH level, and
DAS281-CRP. Hereafter, variables were removed from the
multiple regression models in a backward fashion, based on the
results of multivariate analysis and supposed clinical relevance.
The risk for DAS28-CRP deterioration after 4 months of
treatment (±1–2 months), that is, DDAS28-CRP is expressed as
unstandardized regression coefﬁcient, standard error and a level
of signiﬁcance (p value).
3. Results
Around 1035 patients with diagnosis of RA were included in the
study. A total of 23 patients with juvenile RA/unspeciﬁed juvenile
arthritis were excluded from the study. Patients’ demographic
and clinical characteristics are summarized in Table 1.
3.1. Prevalence of comorbidities
The overall prevalence of different comorbidities in our RA
population is listed in Table 2.
Thyroid diseases were found in 122 (11.8%). Hypothyroidism
was the most common thyroid dysfunction (74/122 (60.6%)) in
our RA patients. Of 108 RA patients with DM, 94 (87%) and 14
(13%) patients were diagnosed with type II and type I,
Emamifar and Hansen Medicine (2018) 97:21 www.md-journal.com
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respectively. Sjogren’s syndrome (10/17 [58.8%]) was most
prevalent comorbid autoimmune diseases followed by inﬂamma-
tory bowl disease (4/17 (23.5%)), systemic sclerosis (1/17
[5.9%]), celiac disease (1/17 [5.9%]), primary biliary cirrhosis
(1/17 [5.9%]). In addition to the 17 patients with other diagnosed
autoimmune diseases, 28 patients had positive autoantibodies
proﬁle; however, the diagnosis of comorbid diseases were not
made at the time of the study and patients were under further
work up.
3.2. Comparison of baseline demographics and RA
related characteristics in patients presented with/without
each speciﬁc comorbidity
Comparison of baseline demographics and RA related character-
istics in patients presented with/without thyroid disease, DM,
primary hyperparathyroidism, vitamin B12 deﬁciency and other
diagnosed autoimmune diseases is summarized in Table 3.
There were signiﬁcant associations between presence of
thyroid diseases and female gender (P value< .001); DM and
greater age (P value< .001); primary hyperparathyroidism and
longer disease duration (P value= .002) as well as other
diagnosed autoimmune diseases and ANA positivity (P value
<.001).
RA patients with thyroid diseases (P value= .001) and other
comorbid autoimmune diseases (P value< .001) had signiﬁcantly
poorer initial response to the RA treatment compared to patients
with isolated RA.
Univariate analyses revealed that age, the presence of thyroid
diseases, the presence of other diagnosed autoimmune diseases,
and DAS281-CRP were signiﬁcantly associated with DDAS28-
CRP (Table 4).
Additionally, multivariate analysis demonstrated that
DDAS28-CRP deterioration was signiﬁcantly correlated to the
presence of thyroid diseases (unstandardized regression coefﬁ-
cient (standard error);  0.188 (0.088), P value= .030) and
presence of other diagnosed autoimmune diseases (0.537
[0.208], P value= .010). There was also a positive correlation
between DDAS28-CRP and DAS281-CRP (0.711 [0.029], P
value< .001).
Table 1
Patients’ demographic and clinical characteristics.
Variables N=1035
Gender, n (%)
Female 656 (63.4%)
Age, years, mean±SD 67.1±14.5
Disease Duration (y), mean±SD 9.6±9.7
IgM-RF n (%)
Positive 606 (58.6%)
Anti-ccp n (%)
Positive 531 (51.3%)
ANA n (%)
Positive 176 (17.0%)
DAS281-CRP, mean±SD 4.5±0.9
DAS284-CRP, mean±SD 3.1±0.8
DDAS28-CRP, mean±SD 1.4±1.0
DDAS28-CRP=DAS281-CRP (at the time of diagnosis) – DAS284-CRP (after 4 months of treatment
initiation±1–2 months), ANA=antinuclear antibody, anti-ccp= anticyclic citrullinated peptide
antibody, DAS281-CRP=disease activity score in 28 joints-C-reactive protein at the time of diagnosis,
DAS284-CRP=disease activity score in 28 joints-C-reactive protein after 4 months of treatment
initiation±1–2 months, IgM-RF= immunoglobulin M rheumatoid factor, SD= standard deviation.
Table 2
Prevalence of different comorbidities in RA patients.
Comorbid disease N=1035
Thyroid diseases, n (%) 122 (11.8%)
Diabetes Mellitus, n (%) 108 (10.4%)
Primary Hyperparathyroidism, n (%) 29 (2.8%)
Vitamin B12 deﬁciency, n (%) 60 (5.8%)
Other diagnosed autoimmune diseases, n (%) 17 (1.6%)
Table 3
Comparison of baseline demographics and RA related characteristics in RA patients presented with/without thyroid disease, diabetes
mellitus, primary hyperparathyroidism, vitamin B12 deﬁciency and other diagnosed autoimmune diseases.
Thyroid
diseases
Diabetes
mellitus
Primary
hyperparathyroidism
Vitamin B12
deﬁciency
Other diagnosed
autoimmune diseases
Variables
Positive
(n=122)
Negative
(n=913)
Positive
(n=108)
Negative
(n=927)
Positive
(n=29)
Negative
(n=1006)
Positive
(n=60)
Negative
(n=975)
Positive
(n=17)
Neg
(n=1018)
Gender n (%)
Female 109 (89.3%)
∗∗
547 (59.9%) 55 (50.9%) 601 (64.8%) 23%(79.3%) 633 (62.9%) 42 (70.0%) 614 (63.0%) 11 (64.7%) 645 (63.4%)
Age, years, mean±SD 68.8±12.0 66.8±14.8 71.9±11.1
∗∗
66.5±14.8 69.9±10.7 67.0±14.6 69.5±14.8 66.9±14.5 68.5±6.0 67.0±14.6
Disease duration,
years, mean±SD
9.9±10.4 9.6±9.6 8.1±7.2 9.8±9.9 15.2±9.6
∗∗
9.5±9.7 9.9±11.3 9.6±9.6 12.8±11.1 9.6±9.7
IgM-RF n (%) 75 (61.5%) 531 (59.3%) 60 (56.1%) 546 (59.9%) 20 (69.0%) 586 (59.3%) 35 (58.3%) 571 (59.6%) 11 (64.7%) 595 (59.4%)
Positive
Anti-ccp n (%) 69 (57.5%) 462 (52.4%) 51 (48.1%) 480 (53.6%) 19 (65.5%) 512 (52.7%) 28 (47.5%) 503 (53.4%) 8 (47.1%) 523 (53.2%)
Positive
ANA n (%) 26 (23.9%) 150 (18.9%) 16 (16.2%) 160 (19.9%) 2 (7.7%) 174 (19.9%) 15 (28.3%) 161 (19.0%) 10 (58.8%)
∗∗
166 (18.8%)
Positive
DAS281-CRP, mean±SD 4.3±0.9
∗
4.5±0.9 4.6±1.1 4.5±0.9 4.4±0.5 4.5±0.9 4.9±0.6 4.5±0.9 4.0±1.3
∗
4.9±0.9
DAS284-CRP, mean±SD 3.2±0.7 3.1±0.8 3.1±0.9 3.1±0.8 3.1±0.6 3.1±0.8 3.1±0.6 3.1±0.8 3.6±1.3
∗
3.1±0.8
DDAS28-CRP, mean±SD 1.1±1.0
∗∗
1.4±1.0 1.4±1.1 1.4±1.0 1.3±0.3 1.4±1.0 1.5±0.7 1.4±1.0 0.5±1.3
∗∗
1.4±1.0
ANA= antinuclear antibody, anti-ccp= anticyclic citrullinated peptide antibody, DAS281-CRP=disease activity score in 28 joints-C-reactive protein at the time of diagnosis, DAS284-CRP=disease activity score
in 28 joints-C-reactive protein after 4 months of treatment initiation±1–2 months and DDAS28-CRP=DAS281-CRP (at the time of diagnosis) – DAS284-CRP (after 4 months of treatment initiation±1–2
months), IgM-RF= immunoglobulin M rheumatoid factor, RA= rheumatoid arthritis, SD= standard deviation.
∗
P value< .05.
∗∗
P value< .005.
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In the backward-stepwise regression analysis, the presence of
thyroid diseases, presence of other diagnosed autoimmune
diseases and DAS281-CRP remained in the model.
4. Discussion
In this cohort study, the observed prevalence of thyroid diseases
in our center was 11.8%, DM 10.4%, primary hyperparathy-
roidism 2.8%, vitamin B12 deﬁciency 5.8%, and other diagnosed
autoimmune diseases 1.6%. We also found signiﬁcant associa-
tions between presence of thyroid diseases and female gender;
DM and greater age; primary hyperparathyroidism and longer
disease duration as well as other diagnosed autoimmune diseases
and ANA positivity. Furthermore, the results of our study
suggested that the initial RA treatment response was signiﬁcantly
poorer among RA patients with thyroid diseases and other
diagnosed autoimmune diseases compared to the patients with
isolated RA.
In the present study, we explored the DDAS28-CRP index
representing initial response to RA treatment after 4 months (±1–
2 months) of treatment. Indeed, the concept of DDAS28-CRP
implemented on the importance of ﬁrst few months after
treatment initiation has been suggested previously.[12] It has
been accepted that patients with RA should be diagnosed and
treated promptly to prevent further joint destruction. The ﬁrst
few months succeeding treatment initiation are pivotal for RA
long-term outcome.[12] A better long-term outcome can be gained
by means of a lower disease activity at 6 months of treatment.
Furthermore, a clinical remission achieved within 3 to 6 months
of RA treatment, regardless of treatment regime, halts the
progression of joint damage.[13,14] Longer follow-up in future
studies is recommended which may add more information to our
ﬁndings.
We previously demonstrated that the prevalence of thyroid
diseases and DMwere higher among a group of RA patients who
were diagnosed according to the new 2010 ACR/EULAR criteria
for RA.[15,38]. Results of the present study are in line with our
previous ﬁndings. Primary hyperparathyroidism in our RA
population was found 3 times more common than in the general
population, considering the increasing prevalence rate in the
elderly (up to 1 per 100 in the elderly).[39,40] The link between
primary hyperparathyroidism and RA is poorly described in the
literature and is limited to few case reports and old data.[41–43]
This might represent the coincidence of 2 common diseases, as
suggested by Crisp et al, or due to the potential effect of enteric
hormones on the calcium metabolism.[44]
As expected, there was a tendency to develop vitamin B12
deﬁciency in our RA patients (5.8% of the patients). This is of
importance due to the fact that hyperhomocysteinemia is an
independent risk factor for cardiovascular disease, considering
the fact that RA patient are seemingly at high risk of
cardiovascular morbidity.[45]
Among RA patients with other autoimmune diseases, Sjogren’s
syndromewas the most prevalent disease. Sjogren’s syndrome is a
common condition in RA.[46] The prevalence of Sjogren’s
syndrome was lower than that of reported prevalence in the
literature (1% vs 4–31%). This might be due to the fact that we
only considered patients whom the diagnosis of Sjogren’s
syndrome was made prior to the conduct of the study. Some
of the patients were under further work up at the time of data
extraction.
Polyautoimmunity has been deﬁned as a presence of more than
one well deﬁned autoimmune disease in an individual patient.
This should be differentiated from overlapping syndrome that is a
partial presence of clinical signs/symptoms of various autoim-
mune diseases. Multiple autoimmune syndrome is used, when 3
or more autoimmune diseases exist at the same time. Poly-
autoimmunity is common in RA and inﬂuenced by clinical and
immunological features.[47] However the authors presume that
the shared autoimmunity is not the only cause of increased
prevalence of comorbidities seen in this study. Genetics, gender,
environmental factors may play roles in the presence of one or
more comorbidities in RA patients.
Of great interest to us, the presence of thyroid diseases and
other autoimmune diseases in our RA population were correlated
with worsening of the DAS28-CRP after 4 months (±1–2
months) of treatment initiation. This conﬁrmed our previous
ﬁndings which were indicative of worse initial treatment outcome
in patients with newly diagnosed RA patients with thyroid
diseases where diagnosis of RA was made according to the 2010
ACR/EULAR criteria for RA.[15] In terms of other diagnosed
autoimmune diseases, for example, Sjogren’s syndrome, earlier
Table 4
Univariate and multivariate analysis of risk factors for DDAS28-CRP.
Variables Univariate analysis Multivariate analysis Backward analysis
Gender 0.028 (0.066) 0.058 (0.056)
Age 0.007 (0.002)
∗∗
0.003 (0.002)
Disease duration 0.000 (0.003) 0.003 (0.003)
IgM-RF 0.055 (0.065) 0.014 (0.068)
Anti-ccp 0.098 (0.065) 0.041 (0.068)
ANA 0.003 (0.086) 0.042 (0.067)
Presence of thyroid diseases 0.315 (0.098)∗∗ 0.188 (0.088)∗ 0.160 (0.081)∗
Presence of primary hyperparathyroidism 0.059 (0.193) 0.008 (0.159)
Presence of diabetes mellitus 0.077 (0.104) 0.023 (0.086)
Presence of vitamin B12 deﬁciency 0.102 (0.136) 0.047 (0.112)
Presence of other diagnosed autoimmune diseases 0.895 (0.249)∗∗ 0.537 (0.208)∗ 0.565 (0.204)∗
TSH Level 0.013 (0.008) 0.011 (0.007)
DAS281-CRP 0.724 (0.027)
∗∗
0.711 (0.029)
∗∗
0.715 (0.029)
∗∗
Results given as unstandardized regression coefﬁcient with standard error and a level of signiﬁcance. Bold values represent the signiﬁcant results of regression analysis.
DDAS28-CRP=DAS281-CRP (at the time of diagnosis) – DAS284-CRP (after 4 months of treatment initiation±1–2 months), ANA= antinuclear antibody, anti-ccp= anticyclic citrullinated peptide antibody,
DAS281-CRP=disease activity score in 28 joints-C-reactive protein at the time of diagnosis, IgM-RF= immunoglobulin M rheumatoid factor, TSH= thyroid stimulating hormone.∗
P value< .05.
∗∗
P value< .005.
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studies were suggestive of poor RA outcome with more
complications and systemic involvement in RA patients with
diagnosed Sjogren’s syndrome.[46]
The strengths of our study were the large sample size and broad
inclusion criteria which minimize the selection bias. Besides, we
explored DDAS28-CRP during the ﬁrst 4 (±1–2 months) months
after start of treatment, since the initial treatment response is a
prognostic factor. Though the prior mentioned strengths, there
were some limitations. The comorbidities reported in the study
were selected by the authors and did not include all types of
comorbidities. Other types of comorbidities may or may not
affect the treatment outcome as well as the prevalence of the
mentioned comorbidities in our study. We did not include RA
patients from general practices as well as rheumatologists in
private practice, since these patients, usually with mild disease,
were not being referred to the hospital. Furthermore, comorbid
diseases diagnosed longer than 10 years ago were not identiﬁed in
this study which may underestimate the prevalence of comorbid
diseases. With respect to the prevalence of different comorbidities
in our study, the prevalence of some of these comorbidities, on the
other hand, might be overestimated due to diagnostic or
reporting bias. Probably, patients with RA are more frequently
offered to screen for recognized comorbidities. Besides, they may
more commonly be diagnosed with comorbidities that a known
association has been found between these comorbidities and RA.
The authors suggest performing a prospective study with a
comparator group without RA to delineate the effect of
mentioned comorbidities in this study, speciﬁcally, thyroid
diseases and other autoimmune diseases, to conﬁrm our results.
The results of this study have a high degree of generalizability due
to broad inclusion criteria.
In conclusion, we provide evidence that patients with RA are at
increased risk of speciﬁc comorbidities. These comorbidities may
affect the outcome of patients with RA. To improve this situation,
periodic assessment of comorbidities should be kept in mind. We
recommend tomeasure TSHandHbA1Con a yearly basis in all RA
patients to diagnose concurrent thyroid diseases or DM. Further-
more, we recommend assessment of autoantibodies directed against
Ro/SSA and La/SSB autoantigens as soon as patients present with
sicca symptoms (dry eyes and dry mouth). If calcium level is
continuously elevated, measurement of PTH should be taken into
account. In case of megaloblastic anemia, vitamin B12 deﬁciency
should be suspected and laboratory measurement of vitamin B12
level and methylmalonic acid should be requested.
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